Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

3-year bladder-intact survival among cCR after four rounds of systemic therapy: 69%.

Proc Natl Acad Sci USA 2026;123(8):e2533449123.PubMed 41706890